drugset / Trial / NCT02959957

Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections

NCT02959957

Phase 4 Completed 157 enrolled Håkan Hanberger
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the ecological impact on the intestinal microbiota and compare the safety and efficacy of temocillin compared to cefotaxime, in empiric treatment of febrile UTI. Half of participants will receive temocillin and the other half will receive cefotaxime.

Timeline

Start
2016-05-20
Primary completion
2019-08
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefotaxime Small molecule 1 g
Comparator Cefotaxime Small molecule 2 g
Subject Temocillin Small molecule 2 g